Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity
Authors
Keywords
-
Journal
JOURNAL OF NANOBIOTECHNOLOGY
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-09
DOI
10.1186/s12951-020-00752-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape
- (2019) Shili Sun et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Tumor targeting via EPR: Strategies to enhance patient responses
- (2018) Susanne K. Golombek et al. ADVANCED DRUG DELIVERY REVIEWS
- Poly(Ethylene Glycol)–Polylactide Micelles for Cancer Therapy
- (2018) Jixue Wang et al. Frontiers in Pharmacology
- CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
- (2018) Stephanie Vairy et al. Drug Design Development and Therapy
- Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy
- (2017) Yu-Cheng Su et al. Nature Communications
- Liposomal Formulations in Clinical Use: An Updated Review
- (2017) Upendra Bulbake et al. Pharmaceutics
- Anti-CD20 antibody treatment of non-Hodgkin lymphomas
- (2016) Marianne Engelhard CLINICAL IMMUNOLOGY
- Development of paclitaxel-loaded liposomal nanocarrier stabilized by triglyceride incorporation
- (2016) Soo-Jeong Lim et al. International Journal of Nanomedicine
- Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas
- (2015) D. Pérez-Callejo et al. CANCER TREATMENT REVIEWS
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
- (2015) Carla Casulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Principles of nanoparticle design for overcoming biological barriers to drug delivery
- (2015) Elvin Blanco et al. NATURE BIOTECHNOLOGY
- Characterization of CD22 expression in acute lymphoblastic leukemia
- (2015) Nirali N. Shah et al. PEDIATRIC BLOOD & CANCER
- One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles
- (2014) Chien-Han Kao et al. BIOMATERIALS
- Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20–243 CrossMab
- (2014) Lei Zhao et al. mAbs
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery
- (2014) Cong Wu et al. Nanoscale Research Letters
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
- (2013) Pavel Strop et al. CHEMISTRY & BIOLOGY
- Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods
- (2012) Keisuke Yoshino et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors
- (2011) Christian Johannes Schmitt et al. ANNALS OF HEMATOLOGY
- A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study
- (2010) M. Hunault-Berger et al. HAEMATOLOGICA
- Antibody derivatization and conjugation strategies: Application in preparation of stealth immunoliposome to target chemotherapeutics to tumor
- (2010) Arehalli S. Manjappa et al. JOURNAL OF CONTROLLED RELEASE
- Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy
- (2010) K.-H. Chuang et al. MOLECULAR CANCER THERAPEUTICS
- The European Medicines Agency Review of Ofatumumab (Arzerra(R)) for the Treatment of Chronic Lymphocytic Leukemia in Patients Refractory to Fludarabine and Alemtuzumab: Summary of the Scientific Assessment of the European Medicines Agency Committee for Medicinal Products for Human Use
- (2010) I. Gravanis et al. ONCOLOGIST
- Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design
- (2010) Emily M. Plummer et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin
- (2009) César Cobaleda et al. BIOESSAYS
- Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
- (2008) H. Maeda et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant
- (2008) Amit K. Sharma et al. JOURNAL OF CONTROLLED RELEASE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started